Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer
Daniel L. Hertz(GTx (United States)), James M. Rae(University of Michigan), Kelley M. Kidwell(University of Michigan), N. Lynn Henry(University of Michigan), Christina L. Gersch(University of Michigan), Daniel F. Hayes(University of Michigan–Ann Arbor), Nicholas J. Seewald(University of Michigan), David A. Flockhart(Indiana University – Purdue University Indianapolis), A-M Storniolo(Indiana University Bloomington), Todd C. Skaar(Indiana University School of Medicine), Zereunesay Desta(Indiana University Health), Vered Stearns(Johns Hopkins University)
Cited by 25
Related Papers
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
|Annals of Oncology|2017|1.3k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k